BioCentury
ARTICLE | Clinical News

Leukemia & Lymphoma Society pipeline update

October 24, 2016 7:00 AM UTC

The Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia (AML). The trial will enroll newly diagnosed AML patients ages >=60. Patients will be screened using a genomic profiling assay from Foundation Medicine Inc. (NASDAQ:FMI, Cambridge, Mass.) for hematologic malignancies. Patients will then be assigned to 1 of 4 treatment arms based on their genetic profiles.

The treatments in the study are all unapproved agents. They include samalizumab (ALXN6000), an anti-CD200 mAb from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN, Cheshire, Conn.); BI 836858, an anti-CD33 mAb from Boehringer Ingelheim GmbH (Ingelheim, Germany); entospletinib (GS-9973), an oral spleen tyrosine kinase (SYK) inhibitor from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.); and enasidenib (AG-221), an inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) from Celgene Corp. (NASDAQ:CELG, Summit, N.J.) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO, Cambridge, Mass.)...